Quantitative Imaging Workshop is a high-impact multi-disciplinary forum for the advancement of quantitative low-dose computerized tomography (LDCT) imaging biomarkers for detection and management of early thoracic disease—lung cancer, COPD and cardiovascular disease—three of the top four leading causes of death in the U.S.
Since 2004, the Prevent Cancer Foundation® has convened a series of annual Workshops to exchange ideas on exciting new biomedical opportunities that this transformational technology enables as well as information on the quality and consistency of policy and advocacy for responsible lung cancer, COPD and cardiovascular screening.
To demonstrate our commitment to making this workshop as widely available as possible and through the generosity of our sponsors, the 2021 Quantitative Imaging Workshop is free to anyone who would like to register.
Since 2004, the Quantitative Imaging Workshop focuses on the advancement of quantitative low-dose computerized tomography (LDCT) imaging biomarkers for detection and management of early thoracic disease—lung cancer, COPD and cardiovascular disease—three of the top four leading causes of death in the U.S.
Beginning in 2013, each year at the Workshop the Prevent Cancer Foundation® presents the James L. Mulshine, M.D., National Leadership Award to an individual who has had a profound impact on reducing the toll these diseases take on the health of Americans and individuals around the world.
Past recipients of this award include:
2019 Meeting Report published in Translational Medicine Communications: Prevent Cancer Foundation quantitative CT imaging workshop XVI: lung cancer, COPD and cardiovascular disease – on the cusp of transformation, Arlington, VA
The Prevent Cancer Foundation® values its partnerships with its supporters and appreciates the impact we make together on increasing cancer screening and early detection. If your organization would like to support the Quantitative Imaging Workshop, or for more information on how you can become a corporate partner, please contact Becca Ginns at firstname.lastname@example.org.
Bristol Myers Squibb